At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 113 enrolled
Drug / intervention
Tislelizumabdrug
Likely dose
Tislelizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab for Locally Advanced or Metastatic Urothelial Bladder Cancer. Completed, enrolled 113 participants across 27 sites in 2 countries.
Detailed Summary
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, South Korea
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedJul 2019
Primary CompletionSep 2019
Study CompletionMar 2021
TodayJul 2026
First PostedJul 1, 2019
Enrollment StartJun 16, 2017
Primary CompletionSep 16, 2019
Study CompletionMar 11, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.0 years ago
Interventions
Tislelizumabdrug
200mg intravenously (IV) every 3 weeks (Q3W)